Who are Danuglipron's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mounjaro, Ozempic, Trulicity, PEG-rhGH Injection + Semaglutide Injection, iGlarLixi, lixisenatide + glargine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/danuglipron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Danuglipron — Competitive Intelligence Brief

Danuglipron (danuglipron) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Metabolic.

marketed GLP-1 receptor agonist GLP-1 receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Danuglipron (danuglipron) — Pfizer. Danuglipron is a small-molecule GLP-1 receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Danuglipron TARGET	danuglipron	Pfizer	marketed	GLP-1 receptor agonist	GLP-1 receptor
Mounjaro	TIRZEPATIDE	Eli Lilly	marketed	Dual GIP/GLP-1 receptor agonist	GIP receptor and GLP-1 receptor	2022-01-01
Ozempic	semaglutide	Novo Nordisk	marketed	GLP-1 Receptor Agonist [EPC]	GLP-1 receptor	2017-01-01
Trulicity	DULAGLUTIDE	Eli Lilly	marketed	GLP-1 Receptor Agonist [EPC]	GLP-1 receptor	2014-01-01
PEG-rhGH Injection + Semaglutide Injection	PEG-rhGH Injection + Semaglutide Injection	Shanghai Zhongshan Hospital	marketed	Growth hormone analog + GLP-1 receptor agonist combination	Growth hormone receptor; GLP-1 receptor
iGlarLixi	iGlarLixi	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Insulin/GLP-1 receptor agonist combination	Insulin receptor; GLP-1 receptor
lixisenatide + glargine	lixisenatide + glargine	Medical University of Warsaw	marketed	GLP-1 receptor agonist + basal insulin	GLP-1 receptor; insulin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-17 — Ozempic · 11097063 · US
2026-07-17 — Ozempic · 8920383 · US
2026-07-17 — Ozempic · 9775953 · US
2026-07-17 — Ozempic · 10220155 · US
2026-08-03 — Ozempic · RE46363 · US
2027-02-27 — Ozempic · 9687611 · US
2027-09-27 — Ozempic · 9457154 · US
2031-12-05 — Ozempic · 8129343 · US
2031-12-16 — Ozempic · 9278123 · US
2031-12-16 — Ozempic · 10086047 · US
2031-12-16 — Ozempic · 10960052 · US
2031-12-16 — Ozempic · 11382957 · US
2032-02-01 — Ozempic · 9132239 · US
2033-03-15 — Ozempic · 10933120 · US
2033-06-21 — Ozempic · 9764003 · US
2033-06-21 — Ozempic · 10335462 · US
2034-05-02 — Ozempic · 10278923 · US
2038-08-24 — Ozempic · 10888605 · US
2041-02-17 — Ozempic · 11318191 · US

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Danuglipron — Competitive Intelligence Brief. https://druglandscape.com/ci/danuglipron. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab